The new Abraxis BioScience, as a standalone publicly traded company, will have its headquarters in Los Angeles, California,
and will employ more than 500 people. The executive committee of Abraxis BioScience will remain in their current positions.
The new board of directors for this business will be determined before, or at the close of, the transaction. -Patricia Van Arnum
Cambridge, MA (June 7)—Genzyme Corp. is investing nearly $140 million in a new 140,000-ft2 biomanufacturing plant in Lyon, France, to replace its smaller plant in nearby Marcy l'Etoile. The new plant, which will
be used to manufacture Genzyme's transplantation treatment, "Thymoglobulin," will have more than twice the manufacturing capacity
of the Marcy facility. Genzyme also is developing a plant in Belgium to produce monoclonal antibodies and proteins, and intends
to expand its Allston Landing protein plant in Boston.